Ophthalmology

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

Increasing the dosage of timolol-dorzolamide fixed combination from twice a day to 3 times a day was found to be safe and significantly more effective in reducing intraocular pressure in patients with open-angle glaucoma, although further research on safety may be warranted.

Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, discusses how greater visual needs are contributing to adverse eye health in younger populations.

Elderly patients who underwent surgery for glaucoma had a greater risk of all-cause and cause-specific mortality than those who did not have surgery, including greater risk of cancer and neurologic cause–related mortality.

A new report suggests corticosteroids likely are not a panacea for ocular surface disease, a potential adverse effect of trabeculectomy.

Findings of the PANORAMA randomized clinical trial show that when patients with severe nonproliferative diabetic retinopathy were treated with intravitreal aflibercept, severity improved over 100 weeks and the likelihood of vision-threatening complications significantly reduced.

A low risk of adverse safety outcomes was observed in anti–vascular endothelial growth factor (VEGF) intravitreal injections performed in office-based and operating room settings, with a higher rate of culture-positive endophthalmitis found in the office setting.

Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, speaks on the impact of screen usage for eyes and trends in eye symptom burden reported amid the pandemic.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

The health insurance provider said it believes up to 20% of all cataract surgeries may be unnecessary, but ophthalmology groups disagree.

Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, discusses the process of cataract development and its prevalence in both older and younger populations.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

The manipulation of key enzymes through methods of gene therapy was shown to provide protection against vision loss from multiple retinal conditions.

Bobeck Modjtahedi, MD, highlights some of the challenges of using telehealth to treat individuals with diabetic retinopathy.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

The development of a successful gene therapy for RPE65-associated inherited retinal disease is a major breakthrough, but it also prompts difficult questions about which patients are good candidates for the therapy.

Hormonal contraceptive use among women of childbearing age was associated with a more than 2-fold higher risk of developing glaucoma, although risk was still relatively low.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

A new meta-analysis finds rigorous evidence lacking; however, existing data suggest preservative-free formulations of beta-blockers may work just as well as preserved beta-blockers in reducing intraocular pressure.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

Over 20 years, 1 in 4 patients with ocular hypertension suffered visual field loss from primary open-angle glaucoma, according to a new study.

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

Classification criteria developed using machine learning will allow doctors to conduct disease-specific research about this collection of inflammatory eye diseases.